In clinical settings, Shiraishi and others have recently reported an ALK-positive NSCLC patient, who was treated with alectinib, lorlatinib, chemotherapy with carboplatin and nanoparticle albumin-bound paclitaxel, and bevacizumab, but the disease progressed. This evidence concerns the gene ALK and non-small cell lung carcinoma.